ArticleCancers2024

C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.

Toshiharu Morikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.